Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003895 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00003895: Completed Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma, sponsored by National Cancer Institute (NCI).
NCT00003895 is a Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003895, a Phase 2 study of Recurrent Melanoma and Stage IIIC Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
Primary Outcome
Frequency measures obtained from each assay will be transformed to (common) logs for purposes of analysis. Repeated measures analyses will be performed on longitudinal data to assess patients' immune response profiles over time. Comparability of assay methods will be assessed with correlation analyses, regression analyses, standard parametric and nonparametric tests, and agreement methods. Pre- and post-immunization T-cell immunity to g209-2M peptide, to HPV16E7 peptide, and to a negative contr
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL HPV 16 E7:12-20
- BIOLOGICAL gp100:209-217(210M)
Study Locations (1)
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT00003895 record still lists
NCT00003895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (79% lower).
The record links to 9 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00003895 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00003895 about?
NCT00003895 is a clinical study titled "Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma". This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
What is the current status of trial NCT00003895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1999-04. Estimated completion is 2013-09.
What conditions does trial NCT00003895 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IIIC Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma.
What interventions are being tested in trial NCT00003895?
The interventions under investigation include: laboratory biomarker analysis (OTHER), HPV 16 E7:12-20 (BIOLOGICAL), gp100:209-217(210M) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003895?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003895 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003895's enrollment target sits among peer trials
36 16th of 23 higher than 8 of 23 other Recurrent Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia